Order — ECLI:EU:T:2026:135
Date: 2026-02-18
Language of the case: English
Court formation: Fourth Chamber
Procedure: Action for annulment
Origin: Czechia;Germany;Denmark;Spain;France;Ireland;Italy;Netherlands;Poland;Romania;Sweden

Order of the General Court of 18 February 2026 – Accord Healthcare France and Others v Parliament and Council (Urban wastewater I) (Joined Cases T-156/25, T-157/25, T-159/25 to T-168/25, T-170/25 and T-171/25) 1 (Actions for annulment – Environment – Urban wastewater treatment – Articles 1, 2, 9, 10 and 30 of, and Annexes I and III to, Directive (EU) 2024/3019 – Extended producer responsibility for medicinal products for human use and cosmetic products – Standing to bring proceedings – Lack of individual concern – Inadmissibility) Language of the case: English Parties Applicant in Case T-156/25: Accord Healthcare France SAS (Lille, France) Applicant in Case T-157/25: Dermapharm AG (Grünwald, Germany) Applicant in Case T-159/25: Adamed Pharma S.A. (Pieńków, Poland) Applicants in Case T-160/25: Fresenius Kabi Deutschland GmbH (Bad Homburg vor der Höhe, Germany), Fresenius Kabi Italia Srl (FKI) (Verona, Italy), Fresenius Kabi Polska sp. z o.o. (Warsaw, Poland) Applicant in Case T-161/25: hameln pharma GmbH (Hamelin, Germany) Applicant in Case T-162/25: Hexal AG (Holzkirchen, Germany) Applicants in Case T-163/25: Exeltis Healthcare, SL (Azuqueca de Henares, Spain), Medical Valley Invest AB (Höllviken, Sweden) Applicant in Case T-164/25: Zakłady Farmaceutyczne Polpharma S.A. (Starogard Gdański, Poland) Applicant in Case T-165/25: Puren Pharma GmbH & Co. KG (Munich, Germany) Applicant in Case T-166/25: E G Labo – Laboratoires Eurogenerics (Issy-les-Moulineaux, France) Applicants in Case T-167/25: Teva Nederland BV (Haarlem, Netherlands), ratiopharm GmbH (Ulm, Germany), Teva Santé (Paris, France), Teva Pharma, SL (Madrid, Spain), Teva Denmark A/S (Søborg, Denmark), Teva BV (Haarlem) Applicants in Case T-168/25: Zentiva k.s. (Prague, Czech Republic), Zentiva Pharma GmbH (Frankfurt am Main, Germany), Winthrop Arzneimittel GmbH (Frankfurt am Main), Zentiva Italia Srl (Milan, Italy), Zentiva France (Paris), Zentiva SA (Bucharest, Romania) (represented by: T. Voland, U. Reese, M. Petite, P. Leven, L.-I. Dietz, M. Steininger and K. Schroeder-Finckh, lawyers) Applicants in Case T-170/25: BGP Products SRL (Bucharest), Meda OTC AB (Stockholm, Sweden), Mylan Germany GmbH (Troisdorf, Germany), Mylan Ireland Ltd (Dublin, Ireland), Mylan Pharmaceuticals Ltd (Dublin), Viatris Healthcare GmbH (Troisdorf), Viatris Santé (Lyon, France) (represented by: K. Roox, M. Navin-Jones, C. Dumont, T. Voland, M. Petite, U. Reese, L.-I. Dietz, M. Steininger, K. Schroeder-Finckh and P. Leven, lawyers) Applicant in Case T-171/25: Laboratorios Normon, SA (Tres Cantos, Spain) (represented by: T. Voland, U. Reese, M. Petite, P. Leven, L.-I. Dietz, M. Steininger and K. Schroeder-Finckh, lawyers) Defendants: European Parliament (represented by: L. Taïeb, W. Kuzmienko and A. Droin, acting as Agents), Council of the European Union (represented by: A. Maceroni and O. Segnana, acting as Agents) Re: By their actions under Article 263 TFEU, in Cases T-156/25, T-157/25, T-159/25 to T-168/25 and T-171/25, the applicants seek, principally, in essence, the annulment of Article 1, Article 2(19), (20) and (26), Articles 9 and 10, and points (c) and (g) of the second subparagraph of Article 30(1) of, and Annex III to, Directive (EU) 2024/3019 of the European Parliament and of the Council of 27 November 2024 concerning urban wastewater treatment (OJ L, 2024/3019), and, in the alternative, the annulment of that directive in its entirety. By their action under Article 263 TFEU, in Case T-170/25, the applicants seek, principally, the annulment of Article 2(14), (17) and (19) and Articles 9 and 10 of, and Annexes I and III to, Directive 2024/3019, and, in the alternative, the annulment of certain parts of those provisions and annexes. Operative part of the order The actions are dismissed as inadmissible. There is no longer any need to adjudicate on the applications to intervene made by Hofmann & Sommer GmbH und Co. KG, Pharma Deutschland eV, Medicines for Europe, Pro Generika eV, Asociación Española de Fabricantes de Sustancias y Especialidades farmacéuticas Genéricas, Bundesverband der Pharmazeutischen Industrie eV, Biogaran SAS, Egis Gyógyszergyár, the European Commission, Bundesverband der Energie- und Wasserwirtschaft (BDEW) eV and Verband Kommunaler Unternehmen (VKU) eV. Accord Healthcare France SAS, Dermapharm AG, Adamed Pharma S.A., Fresenius Kabi Deutschland GmbH, Fresenius Kabi Italia Srl (FKI), Fresenius Kabi Polska sp. z o.o., hameln pharma GmbH, Hexal AG, Exeltis Healthcare, SL, Medical Valley Invest AB, Zakłady Farmaceutyczne Polpharma S.A., Puren Pharma GmbH & Co. KG, E G Labo – Laboratoires Eurogenerics, Teva Nederland BV, ratiopharm GmbH, Teva Santé, Teva Pharma, SL, Teva Denmark A/S, Teva BV, Zentiva k.s., Zentiva Pharma GmbH, Winthrop Arzneimittel GmbH, Zentiva Italia Srl, Zentiva France, Zentiva SA, BGP Products SRL, Meda OTC AB, Mylan Germany GmbH, Mylan Ireland Ltd, Mylan Pharmaceuticals Ltd, Viatris Healthcare GmbH, Viatris Santé and Laboratorios Normon, SA shall bear their own costs and pay those incurred by the European Parliament and the Council of the European Union. Hofmann & Sommer, Pharma Deutschland, Medicines for Europe, Pro Generika, Asociación Española de Fabricantes de Sustancias y Especialidades farmacéuticas Genéricas, Bundesverband der Pharmazeutischen Industrie, Biogaran, Egis Gyógyszergyár, the Commission, BDEW and VKU shall each bear their own costs relating to the applications to intervene. ____________ 1 OJ C, C/2025/2672, 19.5.2025.